Stay updated with breaking news from Soliris Ultomiris. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
/PRNewswire/ -- NovelMed Therapeutics is a clinical-stage biotechnology company focused on developing anti-complement therapies for rare (orphan) diseases....
Author Bio Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.Follow @coryrenauer The recent authorization of AstraZeneca's (NASDAQ:AZN) coronavirus vaccine candidate for emergency supply in the U.K. is getting a lot of attention from investors everywhere. While there are plenty of good reasons to buy AstraZeneca stock right now, you might be surprised to learn that the company's COVID-19 vaccine didn't even make the list. Here are four of the most imp...
AstraZeneca (NASDAQ:AZN) to make a huge bet on Alexion Pharmaceuticals (NASDAQ:ALXN) and its successful drugs for rare diseases. AstraZeneca offered $39 billion for Alexion in a combination of cash and stock, although a lack of enthusiasm for the deal has pressed AstraZeneca shares lower since the announcement. Granted, Alexion Pharmaceuticals isn't the industry's most exciting acquisition target, but this deal will most likely work out well for investors in the long run. Here are three big reasons this deal looks like a win-win for both drugmakers and their shareholders. Image source: Gett...
AstraZeneca (NASDAQ:AZN) announced an agreement to buy Alexion Pharmaceuticals (NASDAQ:ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. Based on AstraZeneca's closing price on Friday, Alexion shareholders are in line to receive about $175 per share. Regulatory hurdles that come with big international mergers are expected to keep this one from completing until the third quarter of 2021. Based on yesterday's closing prices for both stocks, though, AstraZeneca's offer represents a 45% premium. Image source: Getty Images. If regulators don...